Engineering a pH-sensitive humanized infliximab with improved potency and developability using STEM™
Paul D. Entzminger, Kevin C. Entzminger, Jonathan K. Fleming, Alex Samadi, Lisa Yuko Espinosa, Yuko Hiramoto, Shigeru C.J. Okumura, Toshiaki Maruyama
This study humanizes and engineers infliximab to improve its potency and developability, identifying LW2Y as a lead candidate with enhanced pH-dependent properties.
bioRxiv · Aug 19, 2026 · PreprintBioengineering